

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number
WO 01/48183 A3(51) International Patent Classification⁷: C12N 15/10. 9/22, C07K 14/435, C12N 15/66, 15/70, 1/00

(74) Agent: BAYLISS, Geoffrey, Cyril; Boult Wade Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).

(21) International Application Number: PCT/EP00/13149

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date:
22 December 2000 (22.12.2000)

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data:
9930691.2 24 December 1999 (24.12.1999) GB**Published:**

— with international search report

(71) Applicant (for all designated States except US): DEV-GEN NV [BE/BE]; Technologiepark 9, B-9052 Zwijnaarde (BE).

(88) Date of publication of the international search report:
6 December 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): PLAETINCK, Geert [BE/BE]; Pontstraat 16, B-9820 Merelbeke (BE). MORTIER, Katherine [BE/BE]; Paddenhoek 20, B-9830 St.-Martens-Latem (BE). LISSENS, Ann [BE/BE]; Tiensesteenweg 137, B-3010 Kessel-Lo (BE). BOGAERT, Thierry [BE/BE]; Wolvendreef 26g, B-8500 Kortrijk (BE).



WO 01/48183 A3

(54) Title: IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

(57) Abstract: There are described ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that changes in the genetic background of *C. elegans* result in increased sensitivity to double-stranded RNA inhibition.

IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNAINHIBITION

The present invention is concerned with ways of
5 improving the efficiency of double stranded RNA
inhibition as a method of inhibiting gene expression
in nematode worms such as *C. elegans*. In particular,
the invention relates to the finding that the
susceptibility of nematode worms such as *C. elegans* to
10 double stranded RNA inhibition is affected by changes
in the genetic background of the worms.

It has recently been described in Nature Vol 391,
pp.806-811, February 98, that introducing double
stranded RNA into a cell results in potent and
15 specific interference with expression of endogenous
genes in the cell, which interference is substantially
more effective than providing either RNA strand
individually as proposed in antisense technology. This
specific reduction of the activity
20 of the gene was also found to occur in the nematode
worm *Caenorhabditis elegans* (*C. elegans*) when the RNA
was introduced into the genome or body cavity of the
worm.

The present inventors have utilized the double
25 stranded RNA inhibition technique and applied it
further to devise novel and inventive methods of (i)
assigning functions to genes or DNA fragments which
have been sequenced in various projects, such as, for
example, the human genome project and which have yet
30 to be accorded a particular function, and (ii)
identifying DNA responsible for conferring a
particular phenotype. Such methods are described in
the applicant's co-pending application number WO
00/01846. Processes for introducing RNA into a living
35 cell, either *in vivo* or *ex vivo*, in order to inhibit
expression of a target gene in that cell are

additionally described in WO 99/32619.

Several different experimental approaches can be used to introduce double-stranded RNA into nematode worms in order to achieve RNA interference *in vivo*.

5 One of the most straightforward approaches is simple injection of double-stranded RNA into a body cavity. A more elegant solution is to feed the nematodes on food organisms, generally bacteria, which express a double stranded RNA of the appropriate sequence,

10 corresponding to a region of the target gene.

The present inventors have now determined that the phenomenon of RNA interference in nematodes following ingestion of food organisms capable of expressing double-stranded RNA is dependent both on 15 the nature of the food organism and on the genetic background of the nematodes themselves. These findings may be exploited to provided improved methods of double-stranded RNA inhibition.

20 Therefore, according to a first aspect of the present invention there is provided a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence 25 substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild 30 type.

35 *Caenorhabditis elegans* is the preferred nematode worm for use in the method of the invention although the method could be carried out with other nematodes and in particular with other microscopic nematodes, preferably microscopic nematodes belonging to the genus *Caenorhabditis*. As used herein the term "microscopic" nematode encompasses nematodes of

- 3 -

approximately the same size as *C. elegans*, being of the order 1mm long in the adult stage. Microscopic nematodes of this approximate size can easily be grown in the wells of a multi-well plate of the type 5 generally used in the art to perform mid- to high-throughput screening.

It is an essential feature of this aspect of the invention that the nematode has a non wild-type 10 genetic background which confers greater sensitivity to RNA interference phenomena (abbreviated herein to RNAi) as compared to the equivalent wild type nematodes. As illustrated in the accompanying examples, introduction of double-stranded RNA 15 (abbreviated herein to dsRNA) into a non wild-type strain according to the invention results in greater inhibition of expression of the target gene. Depending on the nature of the target gene, this greater level of inhibition may be detectable at the phenotypic level as a more pronounced phenotype.

20 The nematode having non wild-type genetic background may, advantageously, be a mutant strain. Mutations which have the effect of increasing 25 susceptibility of the nematode to RNAi may, for example, affect the stability of dsRNA or the kinetics of dsRNA turnover within cells of the worm or the rate of uptake of dsRNA synthesised by a food organism. Suitable mutant strains include mutant strains 30 exhibiting knock-out or loss-of-function mutations in one or more genes encoding proteins involved in RNA synthesis, RNA degradation or the regulation of these processes.

35 In one preferred embodiment, the nematode is a mutant strain, more preferably a mutant *C. elegans*, which exhibits reduced activity of one or more nucleases compared to wild-type. Suitable strains include mutant strains exhibiting knock-out or loss-of-function mutations in one or more genes encoding

- 4 -

nucleases, such as RNases. A particularly preferred example is the nuc-1 strain. This mutant *C. elegans* strain is known *per se* in the art.

In a second preferred embodiment, the nematode is 5 a mutant strain, more preferably a mutant *C. elegans*, which exhibits increased gut uptake compared to wild-type. Particularly preferred examples of such strains are the so-called *C. elegans* gun mutants described herein. In a still further embodiment, the nematode 10 may be a transgenic worm comprising one or more transgenes which increase gut uptake relative to wild-type.

The term "increased gut uptake" as used herein is taken to mean increased uptake of foreign particles 15 from the gut lumen and may encompass both increased gut permeability and increased gut molecular transport compared to wild-type *C. elegans*.

C. elegans feeds by taking in liquid containing 20 its food (e.g. bacteria). It then spits out the liquid, crushes the food particles and internalises them into the gut lumen. This process is performed by the muscles of the pharynx. The process of taking up 25 liquid and subsequently spitting it out is called pharyngeal pumping. Once the food particles have been internalised via pharyngeal pumping their contents must cross the gut itself in order to reach target sites in the worm. There are multiple factors which effect the uptake of compounds from the gut lumen to 30 the surrounding tissues. These include the action of multi-drug resistance proteins, multi-drug resistance related proteins and the P450 cytochromes as well as other enzymes and mechanisms available for transport 35 of molecules through the gut wall.

C. elegans mutants which exhibit increased uptake 35 of foreign molecules through the gut may be obtained from the *C. elegans* mutant collection at the C.

elegans Genetic Center, University of Minnesota, St Paul, Minnesota, or may be generated by standard methods. Such methods are described by Anderson in Methods in Cell Biology, Vol 48, "C. elegans: Modern 5 biological analysis of an organism" Pages 31 to 58. Several selection rounds of the PCR technique can be performed to select a mutant worm with a deletion in a desired gene. Alternatively, a population of worms could be subjected to random mutagenesis and worms 10 exhibiting the desired characteristic of increased gut uptake selected using a phenotypic screen, such as the dye uptake method described herein.

As an alternative to mutation, transgenic worms 15 may be generated with the appropriate characteristics. Methods of preparing transgenic worms are well known in the art and are particularly described by Craig Mello and Andrew Fire, Methods in Cell Biology, Vol 48, Ed. H.F. Epstein and D.C. Shakes, Academic Press, pages 452-480.

20 Worms exhibiting the desired characteristics of increased gut uptake can be identified using a test devised by the inventors based on uptake of a marker precursor molecule which is cleaved by the action of enzymes present in the gut lumen to generate a marker 25 molecule which produces a detectable signal, such as fluorescence. A suitable marker precursor molecule is the fluorescent dye precursor BCECF-AM available from Molecular Probes (Europe BV), Netherlands. This dye only becomes fluorescent when cleaved by esterases and 30 maintained at a pH above 6. The pH of the gut lumen is usually 5 or below. Thus, any BCECF-AM taken up through the pharynx into the gut lumen is not 35 fluorescent until cleaved and the cleaved portion has entered the cells surrounding the lumen which are at a higher pH. Thus, this dye is able to quickly identify mutant or otherwise modified worms which have increased gut transport or permeability. There is a

gradual increase in fluorescence in the tissues surrounding the gut while the gut lumen remains dark. The fluorescence can be detected at an excitation wavelength of 485 nm and an emission wavelength of 530 nm.

5 Specific examples of gun mutant strains isolated using this procedure which may be used in the method of the invention are strains bg77, bg84, bg85 and bg86, although it is to be understood that the
10 invention is in no way limited to the use of these specific strains. The *C. elegans* gun mutant strain bg85 was deposited on 23 December 1999 at the BCCM/LMG culture collection, Laboratorium Voor Microbiologie, Universiteit Gent, K. L. Ledeganckstraat 35, B-9000, Gent, Belgium under accession number LMBP 5334CB. The
15 phrase "the bg85 mutation" as used herein refers to the specific mutation(s) present in the bg85 strain which is/are responsible for conferring the gun phenotype.

20 It is also within the scope of the invention to use a non wild-type nematode strain, preferable a *C. elegans* strain, having multiple mutations which affect sensitivity to RNAi. A preferred type of multiple mutant is one having at least one mutation which
25 results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type. An example of such a mutant is a *C. elegans* strain having the *nuc-1* mutation and at least one further gun
30 mutation. As exemplified herein, double mutants having the *nuc-1* mutation and a gun mutation exhibit enhanced sensitivity to RNAi as compared to either *nuc-1* or gun single mutants.

35 For the avoidance of doubt, where particular characteristics or properties of nematode worms are described herein by relative terms such as "enhanced"

- 7 -

or "increased" or "decreased" this should be taken to mean enhanced, increased or decreased relative to wild-type nematodes. In the case of *C. elegans*, wild-type is defined as the N2 Bristol strain which is well known to workers in the *C. elegans* field and has been extremely well characterised (see Methods in Cell Biology, Volume 48, *Caenorhabditis elegans: Modern biological analysis of an organism*, ed. by Henry F. Epstein and Diane C. Shakes, 1995 Academic Press; The nematode *Caenorhabditis elegans*, ed. by William Wood and the community of *C. elegans* researchers., 1988, Cold Spring Harbor Laboratory Press; *C. elegans II*, ed. by Donald L. Riddle, Thomas Blumenthal, Barbara J. Meyer and James R. Priess, 1997, Cold Spring Harbor Laboratory Press). The N2 strain can be obtained from the *C. elegans* Genetic Center, University of Minnesota, St Paul, Minnesota, USA.

The food organism for use in the above aspect of the invention is preferably a bacterium such as, for example, a strain of *E.coli*. It will, however, be appreciated that any other type of food organism on which nematodes feed and which is capable of producing dsRNA could be used. The food organism may be genetically modified to express a double-stranded RNA of the appropriate sequence, as will be understood with reference to the examples included herein. One convenient way in which this may be achieved in a bacterial food organism is by transforming the bacterium with a vector comprising a promoter or promoters positioned to drive transcription of a DNA sequence to RNA capable of forming a double-stranded structure. Examples of such vectors will be further described below.

The actual step of feeding the food organism to the nematode may be carried out according to procedures known in the art, see WO 00/01846.

Typically the feeding of the food organisms to the nematodes is performed on standard agar plates commonly used for culturing *C. elegans* in the laboratory. However, the step of feeding the food 5 organism to the nematodes may also be carried out in liquid culture, for example in the wells of 96-well microtitre assay plates.

The inventors have further observed that 10 variations in the food organism can result in enhanced *in vivo* RNAi when the food organism is ingested by a nematode worm.

Accordingly, in a further aspect the invention provides a method of inhibiting expression of a target 15 gene in a nematode worm comprising feeding to said nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a 20 modification selected to provide increased expression or persistence of the doubled-stranded RNA compared to a food organism which does not carry the modification.

The modification present in the food organism can 25 be any modification which results in increased expression of the dsRNA or in increased persistence of the dsRNA. Suitable modifications might include mutations within the bacterial chromosome which affect RNA stability and/or degradation or mutations which 30 have a direct effect on the rate of transcription. In a preferred embodiment, the food organism is an RNase III minus *E. coli* strain, or any other RNase negative strain.

According to a still further aspect of the 35 invention there is provided a method of inhibiting expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide

sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

5 In addition to exhibiting increased sensitivity to RNAi following feeding with food organisms capable of expressing a dsRNA, nematodes which exhibit increase gut uptake as described herein also show increased uptake of DNA molecules capable of producing
10 double-stranded RNA structures following ingestion into a nematode.

In a preferred embodiment, the DNA is in the form of a vector comprising a promoter or promoters orientated to relative to a sequence of DNA such that
15 they are capable of driving transcription of the said DNA to make RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to the promoter or promoters.

20 Several different arrangements of promoters may be used in such a vector. In a first arrangement a DNA fragment corresponding to a region of the target gene is flanked by two opposable polymerase-specific promoters which are preferably identical.

25 Transcription from the opposable promoters produces two complementary RNA strands which can anneal to form an RNA duplex. The plasmid pGN1 described herein is an example of a vector comprising two opposable T7 promoters flanking a multiple cloning site for insertion of a DNA fragment of the appropriate
30 sequence, corresponding to a region of a target gene. pGN8 is an example of a vector derived from pGN1 containing a fragment of the *C. elegans unc-22* gene.

35 In an alternative arrangement, DNA fragments corresponding to a region of the target gene may be placed both in the sense and the antisense orientation downstream of a single promoter. In this case, the sense/antisense fragments are co-transcribed to

- 10 -

generate a single RNA strand which is self-complementary and can therefore form an RNA duplex.

In both of the above arrangements, the polymerase-specific T3, T7 and SP6 promoters, all of 5 which are well known in the art, are useful for driving transcription of the RNA. Expression from these promoters is dependent on expression of the cognate polymerase. Advantageously, the nematode itself may be adapted to express the appropriate 10 polymerase. Expression of the polymerase may be general and constitutive, but could also be regulated under a tissue-specific promoter, an inducible promoter, a temporally regulated promoter or a promoter having a combination of such characteristics. 15 Transgenic *C. elegans* strains harboring a transgene encoding the desired polymerase under the control of an appropriately-regulated promoter can be constructed according to methods known *per se* in the art and described, for example, by Craig Mello and Andrew Fire 20 in Methods in Cell Biology, Vol 48, Ed. H. F. Epstein and D. C. Shakes, Academic Press, pp 452-480.

The advantage of adapting the nematode to express the required polymerase is that it is possible to control inhibition of expression of the target gene in 25 a tissue-specific and/or temporally specific manner by placing expression of the polymerase under the control of an appropriately regulated promoter.

Introduction of DNA into nematodes in accordance with the method of the invention can be achieved using 30 a variety of techniques, for example by direct injection into a body cavity or by soaking the worms in a solution containing the DNA. If the DNA is in the form of a vector as described herein, e.g. a plasmid harboring a cloned DNA fragment between two flanking 35 T7 promoters, then dsRNA corresponding to this DNA fragment will be formed in the nematode resulting in down regulation of the corresponding gene. The

- 11 -

introduced DNA can form an extrachromosomal array, which array might result in a more catalytic knock-out or reduction of function phenotype. The DNA might also become integrated into the genome of the nematode, 5 resulting in the same catalytic knock out or reduction of function phenotype, but which is stably transmittable.

In each aspect of the invention, the double-stranded RNA structure may be formed by two separate 10 complementary RNA strands or a single self-complementary strand, as described above. Inhibition of target gene expression is sequence-specific in that only nucleotide sequences corresponding to the duplex region of the dsRNA structure are targeted for 15 inhibition.

It is preferred to use dsRNA comprising a nucleotide sequence identical to a portion of the target gene, although RNA sequences with minor 20 variations such as insertions, deletions and single base substitutions may also be used and are effective for inhibition. It will be readily apparent that 100% sequence identity between the dsRNA and a portion of the target gene is not absolutely required for inhibition and the phrase "substantially identical" as 25 used herein is to be interpreted accordingly.

Generally sequences which are substantially identical will share at least 90%, preferably at least 95% and more preferably at least 98% nucleic acid sequence 30 identity. Sequence identity may be conveniently calculated based on an optimal alignment, for example using the BLAST program accessible at WWW.ncbi.nlm.nih.gov.

The invention will be further understood with reference to the following non-limiting Examples, 35 together with the accompanying Figures in which:

Figure 1 is a plasmid map of the vector pGN1

containing opposable T7 promoters flanking a multiple cloning site and an ampicillin resistance marker.

5 Figure 2 is a plasmid map of the vector pGN8 (a genomic fragment of the *C. elegans* unc-22 gene cloned in pGN1).

10 Figure 3 is a plasmid map of the vector pGN29 containing two T7 promoters and two T7 terminators flanking *Bst*XI sites. This vector permits cloning of DNA fragments linked to *Bst*XI adaptors.

15 Figure 4 is a plasmid map of the vector pGN39 containing two T7 promoters and two T7 terminators flanking attR recombination sites (based on the Gateway™ cloning system of Life Technologies, Inc).

20 Figure 5 is a plasmid map of the vector pGX22 (a fragment of the *C. elegans* gene C04H5.6 cloned in pGN29).

25 Figure 6 is a plasmid map of the vector pGX52 (a fragment of the *C. elegans* gene K11D9.2b cloned in pGN29).

Figure 7 is a plasmid map of the vector pGX104 (a fragment of the *C. elegans* gene Y57G11C.15 cloned in pGN29).

30 Figure 8 is a plasmid map of the vector pGZ8 (a fragment of the *C. elegans* gene T25G3.2 cloned in pGN39).

35 Figure 9 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the

- 13 -

plasmid pGX22.

Figure 10 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in 5 liquid culture were fed with *E. coli* containing the plasmid pGX52.

Figure 11 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in 10 liquid culture were fed with *E. coli* containing the plasmid pGXGZ8.

Figure 12 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in 15 liquid culture were fed with *E. coli* containing the plasmid pGX104

Example 1

Influence of genetic background on the efficiency of RNAi in *C. elegans*.

5 Introduction

Various different *C. elegans* strains were fed with different bacteria, to test the possibility of RNAi by feeding *C. elegans* with bacteria that produce dsRNA. The possibility of DNA delivery and dsRNA delivery has previously been envisaged by using different bacterial strains. In this experiment the importance of the *C. elegans* strain as receptor of the dsRNA is also shown.

For this experiment the following *E. coli* strains were

15 used:

1. MC1061: F-araD139 Δ (ara-leu)7696 galE15 galK16 Δ (lac)X74 rpsL (Str^r) hsdR2 (r_k⁻ m_k⁺) mcrA mcrB1
 - regular host for various plasmids,
 - Wertman et al., (1986) Gene 49:253-262,
 - Raleigh et al., (1989) in Current Protocols in Molecular Biology eds. Ausubel et al, Publishing associates and Wiley Interscience; New York. Unit 1.4.
- 25 2. B21(DE3): F-ompT(lon) hsdS_B (r_B⁻,m_B⁻); an *E. coli* B strain) with DE3, a λ prophage carrying the T7 RNA polymerase gene.
 - regular host for IPTG inducible T7 polymerase expression,
 - Studier et al. (1990) Meth. Enzymol. 185:60-89
- 30 3. HT115 (DE3): F- mcrA mcrB IN(rrnD-rrnE) 1 λ -rnc14::tr10 (DE3 lysogen: lacUV5 promoter-T7polymerase)
 - host for IPTG inducible T7 polymerase

- 15 -

expression,
- RNaseIII-,
- Fire A, Carnegie Institution, Baltimore, MD,
Pers. Comm.

5

For this experiment the following *C. elegans* strains were used:

1. *C. elegans* N2: regular WT laboratory strain
- 10 2. *C. elegans* *nuc-1*(e1393): *C. elegans* strain with a reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death; ingested (bacterial) DNA in the intestinal lumen is not degraded. Several alleles are described: e1392 (strong allele: has been used for the experiments described below); n887 (resembles e1392) and n334 (weaker allele)
 - Stanfield et al. (1998) East Coast Worm meeting abstract 171,
 - Anonymous, Worm Breeder's Gazette 1(1):17b
 - Hevelone et al. (1988) Biochem. Genet. 26:447-461
 - Ellis et al., Worm breeder's Gazette 7(2):44
 - Babu, Worm Breeder's gazette 1(2):10
 - Driscoll, (1996) Brain Pathol. 6:411-425
 - Ellis et al., (1991) Genetics 129:79-94

For this experiment the following plasmids were used:

30 pGN1: A vector encoding for ampicillin resistance, harbouring a multiple cloning site between two convergent T7 promoters.

35 pGN8: pGN1 containing a genomic fragment of *unc-22*. Decreased *unc-22* expression via RNAi results in a "twitching" phenotype in *C. elegans*.

- 16 -

Experimental conditions

12-well micro-titer plates were filled with approximately 2 ml of NGM agar per well (1 litre of NGM agar: 15g Agar, 1g peptone, 3g NaCl, 1ml

5 cholesterol solution (5 mg/ml in EtOH), with sterile addition after autoclaving of 9.5 ml 0.1M CaCl₂, 9.5 ml 0.1 ml MgSO₄, 25 ml 1M KH₂PO₄/K₂HPO₄ buffer pH 6 and 5 ml nystatin solution (dissolved 10 mg/ml in 1:1 EtOH:CH₃COONH₄ 7.5 M).

10

The dried plates were spotted with approximately 50 μ l of an overnight culture of bacteria. When IPTG induction was required, 50 μ l of a 10 mM stock solution of IPTG was dropped on top of the bacteria lawn, and incubated at 37°C for approximately 4 hours. Individual nematodes at the L4 growth stage were then placed in single wells. In each well 4 nematodes, and the plates were further incubated at 20°C for 6 days to allow offspring to be formed. The F1 offspring of 15 20 the seeded nematodes were tested for the twitching phenotype.

Results

Table 1: Percentage of the offspring that show the twitching phenotype

	MC1061	N2	<i>nuc-1</i>
5	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	0%	0%
	pGN8 + IPTG	0%	0%
10	BL21 (DE3)		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	20% (+)	>90% (++)
	pGN8 + IPTG	20% (+)	>90% (++±)
15	HT115 (DE3)		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	50% (+±)	>90% (++)
	pGN8 + IPTG	80% (++)	>90% (+++)
20			

%: percentage twitchers

+: weak twitching

++: twitching

+++: strong twitching

25

Conclusions

The experiment with *E. coli* MC1061 shows that no twitching could be observed in this experiment.

30

Neither the N2 nematodes nor the *nuc-1* nematodes showed any twitchers. This is to be expected as *E. coli* MC1061 does not produce any T7 RNA polymerase, and hence the unc-22 fragment cloned in pGN8 is not

expressed as dsRNA.

The experiment with *E. coli* strain BL21(DE3) and nematode strain N2 shows expected results. BL21(DE3) harbouring plasmid pGN1 does not result in any twitching as the pGN1 vector is an empty vector. BL21(DE3) harbouring PGN8 results in the expression of unc-22 dsRNA. When this dsRNA is fed to the N2 nematode (indirectly by feeding with the bacteria that produce the dsRNA), this results in a twitching phenotype, indicating that the dsRNA is able to pass the gut barrier and is able to perform its interfering activity.

Surprisingly the RNAi effect of the unc-22 dsRNA was even more pronounced in *C. elegans* strain *nuc-1* than in the wild type N2 strain. Although one may expect that the *nuc-1* mutation results in the non-degradation or at least in a slower degradation of DNA, as the NUC-1 protein is known to be involved in DNase activity, we clearly observe an enhancement of the RNAi induced phenotype in *C. elegans* with a *nuc-1* background. The *nuc-1* mutation has not been cloned yet, but it has been described that the gene is involved in nuclease activity, and more particularly DNase activity. If the NUC-1 protein is a nuclease, it may also have activity on nuclease activity on dsRNA, which would explain the enhanced RNAi phenotype. The *nuc-1* gene product may be a nuclease, or a regulator of nuclease activity. As the mode of action of RNAi is still not understood, it is also possible that the NUC-1 protein is interfering in the mode of action of RNAi. This would explain why a *nuc-1* mutant is more sensitive to RNAi.

35

The experiment with the *E. coli* strain HT115 (DE3)

confirms the experiments with the BL21(DE3) strain. The RNA interference observed with the unc-22 dsRNA is even higher. In comparison with strain BL21(DE3) this could be expected, as HT115(DE3) is a RNase III minus 5 strain, and hence is expected to produce larger amounts of dsRNA, resulting in more prominent RNAi. This indicates further that the RNAi observed in this experiment is the result of the dsRNA produced by the bacteria fed to the *C. elegans*. Feeding *C. elegans* 10 *nuc-1* with HT115(DE3) harbouring pGN8 also results in higher RNA interference phenotype than feeding the same bacteria to *C. elegans* wild-type strain N2. Once again this indicates that improved RNAi can be realised using a nuclease negative *C. elegans* and more 15 particularly with a with the *C. elegans nuc-1* (e1392) strain.

Summary

RNA interference can be achieved in *C. elegans* by 20 feeding the worms with bacteria that produce dsRNA. The efficiency of this RNA interference is dependent both on the *E. coli* strain and on the genetic background of the *C. elegans* strain. The higher the level of dsRNA production in the *E. coli*, the more 25 RNAi is observed. This can be realised by using efficient RNA expression systems such as T7 RNA polymerase and RNAase negative strains, such as RNaseIII minus stains. In this example the level of dsRNA production varied: HT115(DE3)>BL21(DE3)>MC1061.

30 RNA interference is high in *C. elegans* strains that are nuclease negative, or that are influenced in their nuclease activity. This can be realised by using a mutant strain such as *C. elegans nuc-1*.

35 In this example the sensitivity to RNAi varied:
C. elegans nuc-1 >> *C. elegans N2*

Example 2

Improved RNAi by feeding dsRNA producing bacteria in selected *C. elegans* strains-Comparison of the *nuc-1* strain with several mutants which show improved gut uptake (designated herein 'gun' mutants). Strains bg77, bg78, bg83, bg84, bg85, bg86, bg87, bg88 and bg89 are typical gun mutant *C. elegans* strains isolated using selection for increased gut uptake (gun phenotype) with the marker dye BCECF-AM.

10

Experimental conditions:

- 12-well micro-titer plates were filled with approximately 2ml of NGM agar (containing 1ml/l of ampicillin (100 μ g/ml) and 5 ml of 100mM stock IPTG) per well
- the dried plates were spotted with 25 μ l of an overnight culture of bacteria (BL21DE3/HT115DE3) containing the plasmids pGN1 (T7prom-T7prom) or pGN8 (T7prom-unc-22-T7prom)
- 15 - individual nematodes at the L4 growth stage were then placed in single wells, one nematode per well
- the plates were incubated at 20°C for 6 days to allow offspring to be formed
- 20 - the adult F1 offspring of the seeded nematodes were tested for the twitching phenotype
- 25

Results:

Table 2:

20°C/6d	pGN1 HT115DE3	pGN8 BL2DE3	pGN8 HT115DE3	
N2	0	1	1	
bg77	0	1-2	2-3	
bg78	0	1	1-2	
bg83	0	1	1	
bg84	0	1-2	2-3	
bg85	0	1	2-3	
bg86	0	1	2-3	
bg87	0	1	1	
bg88	0	1	1	
bg89	0	1	1	

figure legend:

- 0 = no twitching
- 1 = no to weak phenotype
- 2 = clear phenotype
- 3 = strong phenotype

25 **Conclusions**

- bacterial strain HT115(DE3) shows a better RNAi sensitivity than bacterial strain BL21(DE3)
- the *nuc-1* *C. elegans* strain is a better strain than the Wild-type N2 strain for RNAi sensitivity
- various gun mutants (improved gut uptake mutants) and more particularly the gun mutant strains bg77, bg84, bg85, bg86 show improved sensitivity to RNAi compared to Wild-type.

- 22 -

A double mutant *C. elegans* strain (nuc-1/gun) shows even greater sensitivity to RNAi compared to wild-type:

5 Double mutants were constructed to test the prediction that gun/nuc mutants would even show more enhanced RNAi sensitivity. As an example, the crossing strategy with gun strain bg85 is shown, similar crosses can be conducted with other gun strains, such
10 as bg77, bg84 and bg86.

P0 cross: gun(bg85) x WT males

F1 cross: nuc-1 x gun(bg85)/+ males

15 F2 cross: nuc-1 x gun(bg85)/+; nuc-1/0 males (50%)
nuc-1 x +/++; nuc-1/0 males (50%)

F3 single: gun(bg85)/+; nuc-1 hermaphrodites (25%)
20 +/++; nuc-1 hermaphrodites (75%)

F4 single: gun(bg85); nuc-1 (1/4 of every 4th plate high staining with BCECF)

25 F5 retest: gun(bg85); nuc-1 (100% progeny of F4 singled high staining with BCECF)

To select for the gun phenotype, the fluorescence precursor BCECF-AM is used (obtainable from Molecular
30 probes). The precursor BCECF-AM is cleaved by esterases present in the gut of the worm to generate the dye BCECF which is fluorescent at pH values above 6. This allows selection for worms that have a gun phenotype. BCECF-AM is taken up through the pharynx
35 into the gut lumen and is not fluorescent until it has been cleaved, and the BCECF portion has entered the

cells surrounding the lumen. Wild-type worms will show slower or no increase in BCECF fluorescence.

5 **Example 3**

Improved RNAi feeding in liquid culture using *nuc-1*(e1393) *C. elegans*.

Introduction

10 N2 and *nuc-1* *C. elegans* strains were fed with bacteria producing dsRNAs that give lethal phenotypes via RNAi. For this example RNAi was performed in liquid culture instead of on agar plates. We show here for a number of genes that the RNAi effect is more penetrant using 15 the *nuc-1* strain than the N2 strain, and that RNAi can be performed in liquid.

For this experiment the following *E. coli* strains were used:

20 1. *HT115* (DE3): F- *mcrA mcrB* *IN(rrnD-rrnE)* 1 λ -*rnc14::tr10* (DE3 lysogen: lacUV5 promoter -T7 polymerase)
- host for IPTG inducible T7 polymerase expression
25 - RNaseIII⁻
- Fire A, Carnegie Institution, Baltimore, MD,
Pers. Comm.

For this experiment, following *C. elegans* strains were 30 used:

1. *C. elegans* N2: regular WT laboratory strain
2. *C. elegans* *nuc-1*(e1393): *C. elegans* strain with a 35 reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death;

- 24 -

ingested (bacterial) DNA in the intestinal lumen is not degraded. Several alleles are described:

e1392 (strong allele: has been used for the experiments described below); n887 (resembles e1392) and n334 (weaker allele)

5 - Stanfield et al. (1998) East Coast Worm meeting abstract 171

- Anonymous, Worm Breeder's Gazette 1(1):17b

10 - Hevelone et al. (1988) Biochem. Genet. 26:447-461

- Ellis et al., Worm breeder's Gazette 7(2):44

- Babu, Worm Breeder's gazette 1(2):10

- Driscoll, (1996) Brain Pathol. 6:411-425

- Ellis et al., (1991) Genetics 129:79-94

15

For this experiment, the following plasmids that all give lethal phenotypes in *C. elegans* via RNAi were used:

20 pGX22: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid C04H5.6 corresponding to a member of the RNA helicase family.

25 pGX52: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid K11D9.2b corresponding to sarco/endoplasmic Ca²⁺ ATPase also known as SERCA.

30 pGZ18: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid T25G3.2 corresponding to a chitin like synthase gene.

35 pGX104: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid Y57G11C.15 corresponding to sec-61, a transport protein.

Experimental conditions

- 1 ml overnight cultures of HT115 (DE3) bacteria containing the plasmids pGX22, pGX52, pGZ18 or pGX104 respectively were pelleted and resuspended
5 in S-complete medium, containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.
- 10 µl of this bacterial solution was transferred to a 96-well microtiter plate already filled with
10 100 µl S-complete containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.
- 3 nematodes at the L1 growth stage of N2 and
15 nuc-1 strain were then placed in single wells, 3 L1's per well. Per experimental set up, 16 wells were used (n=16).
- the plates were incubated at 25°C for 5 days to
allow offspring to be formed.
20
- the plates were visually checked and the following phenotypes could be scored per individual well:
25 **no effect:** L1's developed to adults and gave normal offspring.

no F1 offspring: L1's developed to adults and gave no offspring.
30 **acute lethal:** original L1 did not mature and died.

Results

- 35 The results of this experiment are illustrated graphically in Figures 9 to 12. Data are expressed as

- 26 -

a percentage of the total (n=16) on the y-axis for both N2 and *nuc-1* strains.

Conclusions

5 The following genes were tested in this liquid RNAi assay:

- C04H5.6: an RNA helicase. RNAi of this gene interferes with the generation of offspring.
- 10 - SERCA: a sarco/endoplasmic Ca^{2+} ATPase. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- T25G3.2: a chitin like synthase gene. RNAi of this gene causes dead eggs.
- 15 - sec-61: a transport protein. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- 20 - RNAi can be performed under liquid conditions.

As in the previous examples this set of experiments shows that the *nuc-1* *C. elegans* strain is more sensitive to RNAi than the wild-type N2 strain. This 25 is most clear for less penetrant phenotypes such as SERCA and chitin synthase. For strong RNAi phenotypes like the helicase and Sec-61 the difference between the N2 wild-type strain and the *nuc-1* stain is less pronounced.

Example 4**Cloning of pGX22, pGX52, pGZ18 and pGX104 for RNAi**

A set of primers for each gene was designed on the basis of sequence data available in the publicly

5 accessible *C. elegans* sequence database (Acedb).

The cosmid names relate to:

1. **C04H5.6**=member of RNA helicase
- 10 2. **K11D9.2b**=SERCA
3. **Y57G11C.15**=transport protein sec-61
4. **T25G3.2**=chitin synthase like

The following primer sequences were designed:

15

1. **C04H5.6F** 5'-TGCTCAGAGAGTTCTAACGAACC-3'
C04H5.6R 5'-CAATGTTAGTGCTAGGACCACCTG-3'
- 20 2. **K11D9.2bF** 5'-CAGCCGATCTCCGTCTTGTG-3'
K11D9.2bR 5'-CCGAGGGCAAGACAAACGAAG-3'
3. **Y57G11C.15F** 5'-ACCGTGGTACTCTTATGGAGCTCG-3'
Y57G11C.15R 5'-TGCAGTGGATTGGGTCTTCG-3'
- 25 4. **T25G3.2F**
5'-GGGGACAAGTTGTACAAAAAAGCAGGCTATGCCAAGTACATGTCGATTGCG-3'

T25G3.2R

5'-GGGGACCACCTTGTACAAGAAAGCTGGGTTGGAGAACGATTCCGAGAGTTG-3'

30

PCR was performed on genomic DNA of N2 strain *C.*

elegans to give PCR products of the following sizes:

35 1326bp for C04H5.6
1213bp for K11D9.2b

1024bp for Y57G11C.15
1115bp for T25G3.2

5 The PCR fragments of C04H5.6, K11D9.2b and Y57G11C.15
were linked to *Bst*XI adaptors (Invitrogen) and then
cloned into the pGN29 vector cut with *Bst*XI. pGN29
contains two T7 promoters and two T7 terminators
flanking a cloning site which is adapted for
facilitated cloning of PCR fragments, comprising a
10 stuffer DNA flanked by two *Bst*XI sites (see schematic
Figure 3). The resulting plasmids were designated
pGX22 (C04H5.6), pGX52 (K11D9.2b) and pGX104
(Y57G11C.15).

15 The PCR fragment of T25G3.2 was cloned into pGN39 via
recombination sites based on the GATEWAY™ cloning
system (Life Technologies, Inc). pGN39 contains two
T7 promoters and two T7 terminators flanking a cloning
site which facilitates "High Throughput" cloning based
20 on homologous recombination rather than restriction
enzyme digestion and ligation. As shown schematically
in Figure 4, the cloning site comprises *att*R1 and
*att*R2 recombination sites from bacteriophage lambda
flanking a gene which is lethal to *E. coli*, in this
25 case the *ccdB* gene. This cloning site is derived from
the Gateway™ cloning system commercially available
from Life Technologies, Inc. The Gateway™ cloning
system has been extensively described by Hartley et
al. in WO 96/40724 (PCT/US96/10082).

Example 5

Selecting *C. elegans* mutations for increased gut uptake (gun) using marker dye BCECF-AM and *unc-31* as background.

5

The screen was performed in *unc-31*(e928) mutant background, to ensure high amounts of dye in the gut lumen, since *unc-31* mutations show constitutive pharyngeal pumping. The dye (BCECF-AM: 2',7' bis (2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxyethyl ester), obtained from Molecular Probes, is cleaved by intracellular esterases. Fluorescence accumulates in the gut cells upon passage through the apical gut membrane.

10

10 The screen was performed in *unc-31*(e928) mutant background, to ensure high amounts of dye in the gut lumen, since *unc-31* mutations show constitutive pharyngeal pumping. The dye (BCECF-AM: 2',7' bis (2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxyethyl ester), obtained from Molecular Probes, is cleaved by intracellular esterases. Fluorescence accumulates in the gut cells upon passage through the apical gut membrane.

15

Mutagenesis

Day 1: *unc-31* L4 staged worms were mutagenised with EMS (final concentration 50 mM) for 4 hours

Day 2: P0 was divided over several large agar plates

20 Day 6: F1's were collected and dropped on large plates. The number of eggs the F1's layed were checked every hour and de F1's were removed when 10-20 eggs per F1 were counted

25

Day 10: F2 adults were collected and screened with BCECF-AM. Mutations with increased staining of the gut cells after 15-30 minutes exposure to the dye were selected and singled on small agar plates.

30

About 50 initial positives gave progeny which was retested with BCECF-AM (2x) and leucine CMB (1x) 9 of the 50 strains were kept (2 strains : 3 times positive, 7 other strains : twice positive)

35

Table 3: Isolation of mutations for increased staining with BCECF-AM

5	Total P0	Total F1	Total F2	screened chromosomes	number of strains isolated
	(counted)	(estimated)	(calculated)	(estimated)	(counted)
	2251	55618	222472	100000	9

Outcrossing, backcrossing and double construction

- 10 1. backcrossing *unc-31; gun* --> *unc-31; gun*
 - *unc-31; gun* x WT males
 - singled 2x5 WT hermaphrodites F1s (*unc-31/+; gun/+*)
 - singled 50 WT hermaphrodites F2s (1/4 homozygous)
 - select strains segregating 1/4 unc
 - 15 - stain unc strains with BCECF-AM
 - from positive strains pick unc homozygous
 - retest 100 % unc strains with BCECF-AM
 - kept 1 strain (backcrossed)
- 20 2. *unc-31* background was crossed out-->+; *gun*
 - *unc-31; gun* x WT males
 - singled 2x5 WT hermaphrodites F1s (*unc-31/+; gun/+*)
 - singled 50 WT hermaphrodites F2s (1/4 homozygous)
 - select strains which did not segregate unc F3s
 - 25 anymore
 - stain non unc strains with BCECF-AM
 - 7 positive strains were retested with BCECF-AM and finally 1 was selected and kept (outcrossed)
- 30 3. +; *gun* (1x outcrossed) were 2 times backcrossed-->+; *gun* (3x backcrossed)
 - *gun* x WT males
 - WT hermaphrodites x F1 males (*gun/+*)
 - singled 10 WT hermaphrodites F2s (1/2 heterozygous)
 - 35 - singled 50 WT hermaphrodites F3s (1/8 homozygous)

- 31 -

- stain strains with BCECF-AM- retested positives with BCECF-AM and finally 1 was selected and kept

4. *gun* (3x backcrossed) were crossed with *nuc-1*(X)

5 mutant--> *gun; nuc-1*

- *gun* x WT males

- *nuc-1* x *gun/+* males

- *nuc-1* x *gun/+; nuc-1/0* or *+/+; nuc-1/0* males

- singled 10 WT hermaphrodite progeny (*nuc-1*

10 homozygous, ½ heterozygous *gun*)

- singled 40 WT hermaphrodite progeny (1/8 homozygous *gun*)

- stain strains with BCECF-AM

- retested positives with BCECF-AM and finally 1 was
15 selected and kept

Table 6: Strains derived from *gun* mutations

20	<i>gun</i>	<i>unc-31; gun</i>		<i>unc-31; gun</i>		<i>+/; gun</i>			<i>gun; nuc-1</i>	
		original isolate		backcrossed (1x)		outcrossed (1x)		3x b.c.	from 3x b.c.	
	allele number	isolation number	strain number	isolation number	strain number	isolation number	strain number	strain number	strain number	
	bg77	31.4	UG 510	31.4.46.1	UG 556	31.4.34	UG 563	UG 674	UG 777	
25	bg78	37.5	UG 511	37.5.46.4	UG 557	37.5.15	UG 564	UG 675	-	
	bg83	10.2	UG 543	10.2.11	UG 600	10.2.21	UG 586	UG 676	-	
	bg84	7.2	UG 544	7.2.10	UG 601	7.2.15	UG 589	UG 677	UG 774	
	bg85	11.5	UG 545	11.5.29.2	UG 602	2x b.c.	UG 717		UG 775	
	bg86	42.1	UG 546	42.1.4.5	UG 603	42.1.18	UG 587	UG 678	UG 776	
30	bg87	7.1	UG 547	7.1.8.3	UG 604	7.1.22	UG 585	UG 679	-	
	bg88	5.3	UG 548	5.3.9	UG 605	5.3.18	UG 584	UG 680	-	
	bg89	23.4	UG 549	23.4.13.5	UG 606	23.4.3	UG 588	UG 671	-	

SEQUENCE LISTING:

SEQ ID NO: 1 complete sequence of pGN1

5 SEQ ID NO: 2 complete sequence of pGN8

SEQ ID NO: 3 complete sequence of pGN29

10 SEQ ID NO: 4 complete sequence of pGN39

SEQ ID NO: 5 complete sequence of pGX22

SEQ ID NO: 6 complete sequence of pGX52

15 SEQ ID NO: 7 complete sequence of pGX104

SEQ ID NO: 8 complete sequence of pGZ8

20 SEQ ID NO: 9 primer C04H5.6F

SEQ ID NO: 10 primer C04H5.6R

SEQ ID NO: 11 primer K11D9.2bF

25 SEQ ID NO: 12 primer K11D9.2bR

SEQ ID NO: 13 primer Y57G11C.15F

30 SEQ ID NO: 14 primer Y57G11C.15R

SEQ ID NO: 15 primer T25G3.2F

SEQ ID NO: 16 primer T25G3.2R

Claims:

1. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild type.
2. A method as claimed in claim 1 wherein the nematode is a microscopic nematode.
3. A method as claimed in claim 2 wherein the nematode is from the genus *Caenorhabditis*.
4. A method as claimed in claim 3 wherein the nematode is *C. elegans*.
5. A method as claimed in any one of claims 1 to 4 wherein the nematode has a mutant genetic background.
6. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits reduced activity of one or more nucleases compared to wild type.
7. A method as claimed in claim 6 wherein the nematode is *C. elegans* strain *nuc-1*.
8. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits increased

gut uptake compared to wild type.

9. A method as claimed in claim 8 wherein the nematode is mutant *C. elegans* strain bg85.

5

10. A method as claimed in claim 5 wherein the nematode is a mutant strain having at least one mutation which results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type.

11. A method as claimed in claim 10 wherein the nematode is a mutant *C. elegans* strain having the *nuc-1* mutation and the bg85 mutation.

15

12. A method as claimed in any one of the preceding claims wherein the food organism has been engineered to express a double-stranded RNA.

20

13. A method as claimed in any one of the preceding claims wherein the food organism is a bacterium.

25

14. A method as claimed in claim 13 wherein the food organism is *E. coli*.

30

15. A method as claimed in any one of the preceding claims wherein the food organism has been genetically modified to express a double-stranded RNA having a nucleotide sequence substantially identical to a portion of said target gene.

35

16. A method as claimed in claim 15 wherein the food organism contains a DNA vector, the vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of

initiating transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

5

17. A method as claimed in claim 25 wherein the vector comprises two promoters flanking the DNA sequence.

10

18. A method as claimed in claim 26 wherein the two promoters are identical.

15

19. A method as claimed in claim 25 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

20

20. A method as claimed in any one of claims 16 to 20 wherein the nematode or the food organism is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

25

21. A method as claimed in any one of claims 16 to 20 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

30

22. A method as claimed in any one of claims 1 to 21 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

35

23. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a

portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a modification selected to provide increased expression or persistence of the doubled-stranded RNA compared to a food organism which does not carry the modification.

24. A method as claimed in claim 23 wherein the food organism is a bacterium.

10

25. A method as claimed in claim 24 wherein the bacterium is an *E. coli* strain.

15

26. A method as claimed in claim 25 wherein the *E. coli* strain is an RNase III minus strain or any other RNase negative strain.

20

27. A method as claimed in any one of claims 23 to 26 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

30

28. A method of inhibiting expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

35

29. A method as claimed in claim 28 wherein the nematode is a microscopic nematode.

35

30. A method as claimed in claim 29 wherein the nematode is from the genus *Caenorhabditis*.

31. A method as claimed in claim 30 wherein the

nematode is *C. elegans*.

32. A method as claimed in any one of claims 28 to 31 wherein the nematode has a mutant genetic
5 background.

33. A method as claimed in claim 32 wherein the nematode is mutant *C. elegans* strain bg85.

10 34. A method as claimed in any one of claims 28 to 33 wherein the DNA capable of producing a double-stranded RNA structure is a vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of initiating
15 transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

20 35. A method as claimed in claim 34 wherein the vector comprises two promoters flanking the DNA sequence.

25 36. A method as claimed in claim 35 wherein the two promoters are identical.

30 37. A method as claimed in claim 34 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

35 38. A method as claimed in any one of claims 34 to 37 wherein the nematode is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

39. A method as claimed in any one of claims 34

- 38 -

to 38 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

FIG. 1




FIG. 2.




FIG. 3.




FIG. 4.




FIG. 5.




FIG. 6.




FIG. 7




FIG. 8.




FIG. 9.




FIG. 10.




FIG. 11.





FIG. 12.



1
SEQUENCE LISTING

<110> DEVGEM NV

<120> IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

<130> SCB/53711/001

<140>

<141>

<160> 14

<170> PatentIn Ver. 2.0

<210> 1

<211> 3216

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGN1

<400> 1

gagtgccacca	tatgcggtgt	gaaataccgc	acagatgcgt	aaggagaaaa	taccgcata	60
ggcgaattt	taaacgtta	tattttgtta	aaattcgcgt	taaatattt	ttaaatcagc	120
tcatttttta	accaataggc	cgaaatccgc	aaaatccctt	ataaaatcaa	agaatagacc	180
gagatagggt	tgagtgtt	tccagttgg	aacaagagtc	cactattaaa	gaacgtggac	240
tccaaacgtca	aaggcgaaa	aaccgtctat	cagggcgtat	gccccactacg	tgaaccatca	300
cccaaatcaa	gtttttgcg	gtcgagggtgc	cgtaaagctc	taaatcgaa	ccctaaaggg	360
agccccccat	ttagagctt	acggggaaag	ccggcgaacg	tggcgagaaa	ggaagggaag	420
aaagcgaag	gagggggcgc	tagggcgtt	gcaagtgtag	cggtcacgt	ggcgttaacc	480
accacacccg	ccgcgtttaa	tgcggcgtt	caggggcgtt	cattatgcga	ttcaagctgc	540
gcaactgtt	ggaaggcga	tcggtgcggg	ccttttcgt	attacgcag	ctggcggaaag	600
ggggatgtgc	tcaaggcga	ttaagttgg	taacgcagg	gttttccca	tcacgacgtt	660
gtaaaacac	ggcagtgtt	ttgttaatcg	actcaactata	ggcgaattt	gagctcggt	720
cccggggatc	ctctagagtc	gaaagcttct	cgccctatag	tgagtctat	tacagcttga	780
gtattctata	gtgtcaccta	aatagcttgg	cgtaatcatg	gtcatagctg	tttccctgtt	840
gaaattgtt	tccgctcaca	attccacaca	acatacgagc	cggaaagcata	aagtgtaaag	900
cctggggtgc	ctaattggat	agctaactca	cattaattgc	gttgcgctca	ctgcccgtt	960
tccagtcggg	aaacctgtcg	tgccagctgc	attaatgaat	cggccaacgc	gcggggagag	1020
gcgggttgcg	tattgggcgc	tcttccgtt	cctcgctcac	tgactcgctg	cgctcggtcg	1080
ttcggctgcg	gchgagcgta	tcagctact	caaaggcggt	aatacggta	tccacagaat	1140
caggggataa	cgcaggaaag	aacatgttag	aaaaaggcca	gcaaaaggcc	aggaaccgtt	1200
aaaaggccgc	gttgctggcg	ttttcgtata	ggctccggcc	ccctgacgag	catcacaaaa	1260
atcgacgc	aagtcaaggg	tggcgaacc	cgacaggact	ataaaagatac	caggcgttt	1320
cccttggaaag	ctccctcg	cgctctctg	ttccgaccct	gcccgttacc	ggataacctgt	1380
ccgccttct	cccttggga	agcgtggcgc	ttttctcatag	ctcacgcgt	aggtatctca	1440
gttcgggtt	ggtcgttgc	tccaaagctgg	gctgtgtca	cgaacccccc	gttcagcccc	1500
accgcgtgc	cttattccgt	aactatcgtc	tttgatccaa	cccggttaga	cacgacttat	1560
cgccactggc	agcagccact	ggttaacagga	tttagcagagc	gaggatgtt	ggcgtgtca	1620
cagagtctt	gaagtgttgg	cctaactacg	gctacactag	aaggacagta	tttggtatct	1680
gcgctctgt	gaagccagtt	accttcggaa	aaagagttgg	tagctcttga	tccggcaaac	1740
aaaccaccgc	tggtagcggt	ggttttttgg	tttgcaagca	gcagattacg	cgcagaaaaaa	1800
aaggatctca	agaagatctt	ttgatctttt	ctacggggtc	tgacgcctcg	ttgaaacgaaa	1860
actcacgtt	agggatttt	gtcatgagat	tatcaaaaag	gatcttccacc	tagatccctt	1920
taaattaaaa	atgaagttt	aatcaatct	aaagtatata	tgagttaaact	ttqgtctgaca	1980

2

gttaccaatg	cttaatcagt	gaggcaccta	tctcagcgat	ctgtctattt	cgttcatccca	2040
tagttgcctg	actccccgtc	gtgtagataa	ctacgatacg	ggaggggctta	ccatctggcc	2100
ccagtgtcgc	aatgataccg	cgagaccac	gctcaccggc	tccagattt	tcagaataaa	2160
accagccagc	cggaaaggcc	gagcgcagaa	gtggctctgc	aactttatcc	gcctccatcc	2220
agtctattaa	ttgttgcgg	gaagctagag	taagttagttc	gccagttaat	agtttgcgca	2280
acgttgttgg	cattgttaca	ggcatcggtt	tgtcacgctc	gtcggttgg	atggcttcat	2340
tcagctccgg	ttcccaacga	tcaaggcgag	ttacatgatc	ccccatgtt	tgcaaaaaag	2400
cggtagtctc	cttcggtctt	ccgatcggtt	tcagaagtaa	gttggccgca	gtgttatcac	2460
tcatggttat	ggcagactg	cataattctc	ttactgtcat	gccatccgta	agatgctttt	2520
ctgtgactgg	tgagttactca	accaagtcat	tctgagaata	ccgcgcgg	cgaccgagg	2580
gctcttggcc	ggcgtaataa	cgggataata	gtgtatgaca	tagcagaact	ttaaaagtgc	2640
tcatcatgg	aaaacgttct	tcggggcgaa	aactctcaag	gatcttaccg	ctgttggat	2700
ccagttcgat	gtaaaccact	cgtgcaccca	actgatcttc	agcatctttt	actttcacca	2760
gcgtttctgg	gtgagcaaaa	acaggaaggc	aaaatccgc	aaaaaggga	ataaggcga	2820
cacggaaatg	ttgaataactc	atactcttc	tttttcaata	ttattgaacg	atttatcagg	2880
gttattgtct	catgagcgga	tacatatttgc	aatgtattt	aaaaaataaa	caaatagggg	2940
ttccgcgcac	atttccccga	aaagtgcac	ctgacgtcta	agaaaaccatt	attatcatga	3000
cattaaccta	taaaaaatagg	cgtatcacga	ggccctttcg	tctcgcgcgt	ttcgggtatg	3060
acgggtaaaa	cctctgacac	atgcagctcc	cggagacgg	cacagcttgt	ctgtaaagcgg	3120
atgccgggag	cagacaagcc	cgtcaggccg	cgtcagcggg	tgttggcggg	tgtcggggct	3180
ggcttaacta	tgcggcatca	gagcagatttgc	tactga			3216

<210> 2
<211> 4620
<212> DNA
<213> Arti

62201

<223> Description of Artificial Sequence: Plasmid pGN8

<400> 2

gatccgaatc tccatgtctg ttaaacggct tgacacggaa ttatattca tgcccttgag 60
tcaaatcgta aacgtggaa ttggtatctc tgctctctcc gcaagcagtc catctgccag 120
tggcagcatc ttgtttca atgacatagt gactgattc agctcctcca tcatcttctg 180
gttccttcca tgcaagatca catccatct tgacaatatt agtgacatcg agaggtccac 240
gtgggcttga tggatgatca agaacagtaa ccttcaactc agcagtgtca gttcattct 300
cgttctctgc cttgatgata taggttctcg tatccgaacg caaagcttc ttacatggg 360
atttagtctt gccgtctca ttgttcaact tcatacgatc atcagattcg actgtgttc 420
cttcgaaagt ccaagtaatt gttggaggta gttcaccact gactggaatg ttcaatgaga 480
agtcttgccc agccttgacc ttgattctt gaatcgagtt acgatcgatg actgtggaa 540
ctataattta attcaatgtat tatttagtaat tgatttagac tcttaccatt tctagcctt 600
gcaacagctg atgctgaatc agatggatct cccaaatctcg cttgttctt ggcacggatt 660
ctgaattctgt acettgtatcc ttcccttgaga ttccaaacag tagcattctg ttgtccagct 720
ggaacatgg caacgtcatt ccagaatggc gagaactctg ctttcatctc aacaacgtat 780
tcctcgatgg gaggaccacc gtcgttgc ggtggcttcc attcaaggct aacatgatcc 840
ttatcccaat ctagaatttc aggagcattt gtcttcctg gcttgcataa tggatcttgg 900
gcaagtgtgg ttccgaaggat ctc当地atgg tcggactctc cttcagcatt gacggcagcg 960
acacggaaat gaaaatcaaa atttgttgcattt caatttgcattt caagattaa aaattctc 1020
tttatatca tggccaggaa taagaccgtc aacaacagct gtatgttcaat ctccagcgac 1080
cttgcagct ggaacccatc ttccacttgc agtacgtac ttttcgatca catagttttc 1140
aatttggaaata cttccatcat catctggtc acgccaattt aaagtgcacat gatcaccatg 1200
aacatcgaa acatctaattt gaccatttgg agaagttggc ttgtctgaaa attttaaaata 1260
taaccaattt aatttgaagaa aactaatgtctt caccataaac attgtatctt acagggtgtt 1320
catcttctcc atttgcattt acagcttgc tagtggaaatg tccactgtct ccacgttcca 1380
tttgccttcac aaccagctt gattggattt ctgggttac aagcttctcg ccctatagt 1440
agtctgttta cagcttgatg attctatgt gtcacccaaa tagcttggcg taatcatgg 1500
catagctgtt tcctgtgtga aatttgcattt cgctcacaat tccacacaaat atacgagccg 1560
gaagcataaa gtgtaaagcc tgggggtgcct aatgagtgatg ctaactcaca ttaatttgcgt 1620

tgcgctcaact gcccgttcc cagtcggaa acctgtcgta ccagctgcataatgaatcg 1680
 gccaacgcgc ggggagaggc ggtttcgta ttggcgctc ttccgcttcc tcgctcaact 1740
 actcgctcgctc ctcggcgtt cggctgcggc gagcgggtatc agctcaactca aaggcggtaa 1800
 tacggttatac cacagaatca ggggataacg caggaaagaa catgtgagca aaaggccagc 1860
 aaaaggccag gaaccgtaaa aaggccggt tgctggcggtt ttgcataagg ctccgcccc 1920
 ctgacgagca tcacaaaaat cgacgctcaa gtcagagggt gcgaaaccgg acaggactat 1980
 aaagatacca ggcgtttccc cctggaaagct ccctcggtc ctctctgtt cccgaccctgc 2040
 cgcttacccgg atacctgtcc gccttctcc cttcgggaaag cgtggcggtt tctcatagct 2100
 cacgtgttagt gtatctca gtcgggttagg tggttcgctcaagctggc tggtgcacg 2160
 aaccggccgt tcagccgcac cgctgcgcct tatccggtaa ctatcgctt gagtccaaacc 2220
 cggtaagaca cgacttacg ccactggcag cagccactgg taacaggatt agcagagcga 2280
 ggtatgtagg cggtgctaca gaggcttgc agtggggcc taactacggc tacactagaa 2340
 ggacagtatt tggtatctgc gtcgtctga agccaggtaatccggaaaa agagttggta 2400
 gctttgatc cggcaaacaa accaccgctg gtacgggtgg ttttttggtt tgcaagcagc 2460
 agattacgcg cagaaaaaaa ggatctcaag aagatctttt gatctttct acgggggtctg 2520
 acgctcagtg gaacgaaaac tcacgttaag ggattttggt catgagattatcaaaaaagga 2580
 tcttcaccta gatccttta aattaaaaat gaagttttaa atcaatctaa agtataatatg 2640
 agtaaacttg gtctgacagt taccatgtt taatcagtga ggcacccatc tcagcgatct 2700
 gtctatccgtt ttcatccata gttgcctgac tcccgctgt gtagataact acgataccgg 2760
 agggcttacc atctggccccc agtgcgtcaaa tgataccggc agaccacgc tcaccggctc 2820
 cagatttatac agcaataaac cagccagccg gaagggccga ggcgcagaagt ggtcctgca 2880
 ctatccgc ctccatccag tctattaaatt gttgcgggaa agctagagta agtagttcgc 2940
 cagttatag tttgcgcaac gttgttggca ttgcgtacagg catcggtgt tcacgctcgt 3000
 cgttggat ggcttcattc agctccgggtt cccaaacgatc aaggcgagtt acatgatccc 3060
 ccatgttgcg caaaaaaagcg gttagctcct tcggccttcc gatcggtgtc agaagtaagt 3120
 tggccgcagt gttatcactc atgggtatgg cagccactgca taattctt actgtcatgc 3180
 catccgtaaatgcttttct gtgactgggt agtactcaac caagtcattc tgagaataacc 3240
 ggcgcggcgc accgggttc tcttgcggg cgtcaataac ggataatagt gtatgacata 3300
 gcagaactttt aaaaatgttc atcattggaa aacgttcttc gggggaaaaa ctctcaagga 3360
 tcttaccgtt gttgagatcc agttcgatgt aacccactcg tgacccaaatc tgatcttcag 3420
 catcttttac tttcaccagc gtttctgggt gagaaaaaac aggaaggcaa aatgcgcaca 3480
 aaaaggaaat aaggcgaca cggaaatgtt gaataactcat actcttcctt tttcaatatt 3540
 attgaagcat ttatcagggtt tattgtctca tgagcggata catattgaa tttttaga 3600
 aaaataaaaca aataggggtt cccgcgcacat ttcccgaaaa agtgcacccat gacgtctaa 3660
 aaaccattat tatcatgaca ttaacctata aaaataggcg tatcacgagg cccttcgtc 3720
 tcgcccgttt cgggtgtgac ggtggaaacc tctgacacat gcaagctcccg gagacgggtca 3780
 cagcttgcgtt gtaagcggat gcccggagca gacaagcccc tcagggcgcg tcagcgggtg 3840
 ttggcgggtg tcgggctgg ctttaactatg cggcatcaga gcagattgtt ctgagagtgc 3900
 accatatgcg gtgtgaaata cccgcacagat gcgtaaggag aaaataccgc atcaggcgaa 3960
 attgtaaacg ttaatatttt gttaaaattc gcgtaataata tttgttaat cagctcattt 4020
 tttaaccaat aggccgaaat cggcaaaatc cttataataat caaaagaata gaccgagata 4080
 gggttgagtg ttgttccagt ttggaaacaag agtccactat taaagaacgt ggactccaaac 4140
 gtcaaaaggcg gaaaaacccgt ctatcaggcc gatggcccac tacgtgaacc atcacccaa 4200
 tcaatttttt tgcggcgtgag gtgcgttaaa gctctaaatc ggaaccctaa agggagcccc 4260
 cgatttagag ctgtacgggg aaggccggcg aacgtggcga gaaaggaaagg gaagaaagcg 4320
 aaaggagcgg ggcgttagggc gctggcaagt gtacgggtca cgctgcgcgt aaccaccaca 4380
 ccccccggc ttaatgcgcc gtcacgggc gcgccattc gccattcagg ctgcgcact 4440
 gttggaaagg gcgatcggtg cggccctt ccgttattacg ccagctggcg aaagggggat 4500
 gtgcgtcaag gcgatggat tggtaacgc cagggttttc ccagtcacga cgttggaaaa 4560
 cgacggccag tgaattgtaa tacgactcac tataaggcga attcgagctc ggtacccggg 4620

<210> 3

<211> 4756

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGX22

<400> 3
 tgctcagaga gtttctcaac gaacccgatt tggctagtttta taggttaattt tttagaacatt 60
 tacaaaaaaca gcaaaaaaaac caaacattca ggatttttgtt ttttaattaa gaaaaaaatc 120
 gatcgcttt aaatttttaat caataacttcg aataaaaccca aaaaaaaaacg aaaaaaaaatc 180
 ctgtttccag tgtaatgatg tattcggtt agtcaaaagat ctgcaacact tgacgctgaa
 ttccgggacg cagattcccg tcgacgccc tatcgtcaca ttttggatt tctgactgg
 ggtcgaaagc actgggatcg tgcccagtga tttcgaggcg attttttcta
 aaaaacttttta caaatttttta aaaaactttt catttttttc
 gaacaaattt gaagttttcc ctgaaatgc tattctctcg
 gaaaatttct aactgtaaaa tatagaaaat gtaagcattc
 ccagaaatata taacagaaaa ttacattttt tttttggga
 caaaaaatta ttttttttaat caaatttggt tcggtgaatt
 acattccacg catttctagt acattgcccag cacaatggat
 gtcgcggccg cgactctcta acgggtctt aggggtttt
 tattctatag tgtcaccaa aaattgttat ccgctcacaa
 ctgggtgtcc taatgagtga ccagtccgga aacctgtcg
 cggttgcgt attggcgcgt tcggctgcgg cgagcggat
 aggggataac cgagggaaaga aaaggcccg ttgtggcgt
 tcgacgctca agtcagaggt ccctggaaagc tccctctgc
 cgccttctc cttcgggaa ttctggtag gtcgttcgt
 ccgctgcgc ttatccggta gcaactggca
 agagttcttg aagtgggtgc cgctctgtc aagccagtt
 aaccaccgct gtagccgtg agatctcaa gaagatcctt
 ctcacgttaa gggattttgg aaattaaaaaa tgaattttt
 ttacaatgc ttaatcgtg agttgcgtc ctccccgtcg
 cagtgcgtca atgataccgc ccagccagcc ggaaggggccg
 gtcttataat tggccggg cgttggcgc attgctacag
 cagctccggc tcccaacgc ggttagctcc ttctggcctc
 catggttatg gcagcaactgc tggactgtt ggtactcaa
 ctcttgcggc gcgtcaatac

catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tggtagatc 3420
 cagttcgatg taaccactc gtgcacccaa ctgatcttca gcatcttta ctttcaccag 3480
 cgttctggg tgagcaaaaa caggaaggca aaatgcgcgca aaaaaggaa taagggcgac 3540
 acgaaaatgt tgaatactca tactcttcct tttcaatat tattgaagca tttatcaggg 3600
 ttattgtctc atgagcgat acatattga atgtatttag aaaaataaac aaataggggt 3660
 tccgcgcaca tttccccgaa aagtgcacc tgacgtctaa gaaaccatta ttatcatgac 3720
 attaacctat aaaaatagc gtatcacgag gccccttcgt ctcgcgcgtt tcggtgatga 3780
 cggtaaaaac ctctgacaca tgcagctccc ggagacgggtc acagcttgc tctaagcgg 3840
 tgccgggagc agacaagccc gtcaggcg 3900
 gcttaactat gcggcatcag agcagattgt actgagagtg caccatatgc ggtgtgaat 3960
 accgcacaga tgcgtaaagga gaaaataccg catcaggcga aattgtaaac gtaatattt 4020
 tggtaaaatt cgcgttaat atttggtaa tcaagtcattt ttttaaccaa taggcccggaa 4080
 tcggtaaaaat cccttataaa tcaaaaagaat agaccggat agggttggat gttgttccag 4140
 tttggaaacaa gagtccacta ttaaagaacg tggactccaa cgtcaaaagg cgaaaaaccg 4200
 tctatcaggg cgatggccca ctacgtgaac catcacccaa atcaagttt ttgcggtcg 4260
 ggtgcgtaa agctctaat cggaaaccctaa aaggggagccc ccgatttgc gcttgcgg 4320
 gaaagccggc gAACGTGGCG agaaaggaaag ggaagaaagc gaaaggagcg ggcgcctagg 4380
 cgctggcaag ttagcggtc acgctgcgcg taaccaccac accccggcg cttaatgcgc 4440
 cgctacaggg cgcggtccatt cgccattcag gtcgcacac tggggaaag ggcgcgtcg 4500
 gccccctct tcgctattac gccagctggc gaaagggggg tggctgcaaa ggcgattaa 4560
 ttggtaaoc ccagggtttt cccagtcacg acgttgc ttttgcggcc gttgttgc 4620
 atacgactca ctataggcg aattcaaaaa acccctcaag acccgtttag aggccccaa 4680
 gggttatgtct agtgaatttgc cggggatctt ctagagatcc ctcgacctcg 4740
 agatccattt tgctgg 4756

<210> 4

<211> 4643

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGX52

<400> 4

gagtgccacca tatgcgggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcata 60
 ggcgaaattt taaacgttaa tattttgtta aatttcgcgt taaatattt ttaaatcagg 120
 tcattttta accaataggc cggaaatcgcc aaaaatccctt ataaatcaaa agaatagacc 180
 gagataggggt ttagtgcgtt tccagtttgg aacaagagtc cactattaaa gAACGTGGAC 240
 tccaaacgtca aaggggcgaaa aaccgtctat caggcgatg gcccactacg tgaaccatca 300
 cccaaatcaa gtttttgcg gtcgagggtc cgttaaagctc taaatcgaa cccctaaagg 360
 agcccccgat ttagagcttg acggggaaag cggcgcaacg tggcgagaaa ggaagggaaag 420
 aaagcgaaag gaggcgccg tagggcgctg gcaagtgtag cggtcacgcg ggcgttaacc 480
 accacaccccg cgcgcgtttaa tgcggcccta caggcgctg ccattcgcca ttcaggctgc 540
 gcaactgttgc ggaaggcgca tcggcgccgg cctcttcgtt attacgcgg ctggcgaaag 600
 ggggatgtgc tgcaaggcgca ttaagttggg taacgcggcagg gttttcccg tcacgcgtt 660
 gtaaaacgcg ggcgcgtttaa ttttgcgtt attacgttgc acgttgcgtt gggcgaaatcc 720
 tcaagacccg ttttagaggcc ccaaggggtt atgtctgttgc attctgcagg gtacccggg 780
 atcccttaga gatccctoga cctcgagatc cattgtgcgt gcagccgatc tccgtcttgc 840
 gaagatctac tccaccacca tccgtatcga tcaatccatc ctcacccgg aatctgtgtc 900
 tggatcaag cacaccgact ctgtgcaga tccacgcgtt gttaccagg acaagaagaa 960
 ttgtctgttc tcgggaacca atgtcgatc tggaaaggct cgtggatcgt tcttcggaaac 1020
 cggattgacc actgaaatcg gaaagatccg taccgaaatg gctgagaccg agaatgagaa 1080
 gacaccactt caacagaagt tggacgaaatt cggagagcaa ctttccaagg ttatctctgt 1140
 tatttgcgtt gctgtttggg ctatcaacat tggacatttc aacgatcccg ctcacgggtgg 1200
 atcatgggtt aaggggagccaa tctactactt caaaatcgcc gttgcgttgc cctgcgtgc 1260
 tattccagaa ggacttccag ctgtcatcac cacgtgcctt gcccctggaa ctcgcccgtat 1320
 ggccaaagaag aacgctattt gaaatccct tccatccgtc gaaactcttgc gatgcacatc 1380
 tggatctgc tctgacaaga ctggaaacttccatc caccaccaac cagatgtgtc tggatctgc 1440

gttcatcgct	ggacaagctt	ctggagacaa	catcaacttc	accgagttcg	ccatctccgg	1500
atccacccat	gagccagtgc	gaaagggttc	caccaatgg	cgtgaatca	acccagctgc	1560
tggagaattt	gaatcactca	ccgagttggc	catgatctgc	gctatgtgc	atgattcatc	1620
tgttggattac	aatgagagcca	agaagatcta	cgagaaagtc	ggagaagcca	ctgaaactgc	1680
tcttattcggt	cttgcgtgaga	agatgaatgt	tttgcgaacc	tcgaaagccg	gacttccacc	1740
aaaggagctc	ggaggagttt	gcaaccgtgt	catccaacaa	aatggaaga	aggagttcac	1800
actcgagttc	tcccgtgatc	gtaaatccat	gtccgcctac	tgcttccag	cttccggagg	1860
atctggagcc	aagatgttgc	tgaaggggac	cccagaagga	gttctcgaa	gatgcaccca	1920
cgtcagagtt	aacggacaaa	aggttccact	cacctctgcc	atgactcaga	agattgttga	1980
ccaatcgctg	caatacggaa	ccggaagaga	tacccttcgt	tgtctgc	tcggccagca	2040
caatggatct	cgagggatct	tccataccat	ccagttctgc	gcctgcaggt	cgccgcccgcg	2100
actctctaga	cgcgtaaagct	tactagcata	acccttggg	gcctctaacc	gggtcttgag	2160
gggttttttg	agcttctgc	cctatagtga	gtcgatttac	agcttgatgt	ttctatagt	2220
tcacctaata	agcttggcgt	aatcatggtc	atagctttt	cctgtgtgaa	attgttatcc	2280
gctcacaaatt	ccacacaaca	tacgagccgg	aagcataaaag	tgtaaaagct	gggtgccta	2340
atgagtgagc	taactcacat	taattgcgtt	gcgcactgt	cccgctttt	agtccggaaa	2400
cctgtcg	cagctgcatt	aatgaatccg	ccaaacgcgc	ggggagagggc	gtttcgat	2460
tgggcgtct	tccgcttct	cgctcaactga	ctcgctgcgc	tcggtcg	ggctcgccgc	2520
agcggatca	gctcaactcaa	aggcggtaat	acggttatcc	acagaatcag	gggataacgc	2580
aggaaagaac	atgtgagcaa	aaggccagca	aaaggccagg	aaccgtaaaa	aggccgcgtt	2640
gctggcg	ttcgataggc	tccgcccccc	tgacgagcat	cacaaaaatc	gacgctcaag	2700
tcagagggtgg	cgaaaacccga	caggactata	aagataccag	gcgttcccc	ctggaaagctc	2760
cctcgtgcgc	tccctgttc	cgaccctgcc	gcttaccgg	tacctgtccg	ccttctccc	2820
ttcgggaagc	gtggcgctt	ctcatagctc	acgctgttag	tatctcagtt	cggtgttagt	2880
cgttcgctcc	aagctgggc	gtgtgcacga	acccccgtt	cagcccgacc	gctgcccctt	2940
atcccgtaac	tatcgtcttgc	agtccaaaccc	ggtaagacac	gacttatcgc	cactggcagc	3000
agccacttgtt	aacaggattta	gcagagcgag	gtatgttagc	ggtgc	actgttgc	3060
gtggtggcct	aactacggct	acactagaag	gacagtattt	ggtatctgc	ctctgtgtaa	3120
gccagttacc	ttcggaaaaaa	gagttggtag	ctcttgatcc	ggcaaaacaaa	ccacccgtgg	3180
tagcggttgtt	ttttttttt	gcaagcagca	gattacgcgc	agaaaaaaaaag	gatctcaaga	3240
agatcccttg	atctttctta	cggggctc	cgctcagttt	aacggaaaat	cacgttaagg	3300
gattttggtc	atgagattat	caaaaaggat	cttcacccat	atccctttaa	attaaaaatg	3360
aagttttaaa	tcaatctaaa	gtatataatg	gtaaacttgg	tctgacagg	accaatgttt	3420
aatcgttgag	gcacccatct	cagcgatctg	tctatttcgt	tcatccatag	ttgcctgact	3480
ccccgtcg	tagataacta	cgatacggga	gggcttacca	tctggcccca	gtgctcaat	3540
gataccgg	gaccacgc	cacccgctcc	agatttatca	gcaataaaacc	agccagccgg	3600
aaggggccag	cgcagaagtg	gtcctgcaac	tttatccgc	tccatccagt	ctattaattg	3660
ttgcccggaa	gctagagtaa	gtagttcgcc	agttaatagt	ttgcgcac	ttgttggcat	3720
tgctacaggc	atcggtgt	cacgctcg	gttggatg	gcttcattca	gctccgggtc	3780
ccaaacgatca	aggcgagtt	catgatcccc	catgttgc	aaaaaaagg	ttagctc	3840
cgggtcctcc	atcggtgtca	gaagtaagtt	ggccgcagtg	ttatcactca	tggttatggc	3900
agcaactgc	aattctctta	ctgtcatg	atccgtaaaga	tgcttttgc	tgactggta	3960
gtactcaacc	aagtcttct	gagaataccg	cgcccgccg	ccgagttgt	cttgc	4020
gtcaatacgg	gataatagt	tatgacatag	cagaacttta	aaagtgc	tcatggaaa	4080
acgttcttcg	gggcgaaaaac	tctcaaggat	cttacccgt	ttgagatca	gttcgtat	4140
accacactgt	gcacccat	gatcttc	atctttact	ttcaccagcg	tttctgggt	4200
agcaaaaaca	ggaaggccaa	atgcgc	aaaggaaata	agggcacac	ggaatgtt	4260
aataactcata	ctttccctt	ttcaatatta	ttgaagcatt	tatcagggtt	attgtctcat	4320
gagcggat	atatttgaat	gtattnagaa	aaataaacaa	ataggggtt	cgccgcacatt	4380
tccccgaaaa	gtgccacctg	acgtctaaga	aaccattatt	atcatgacat	taacccataa	4440
aaataggcg	atcacgaggc	ccttctgc	cgccgc	ggtgatgac	gtgaaaac	4500
ctgacacatg	ca	agacgtc	agctgtctg	taagcggat	ccgggagcag	4560
acaagccgt	ca	agcgggtgt	tggcggtgt	cgggcgttgc	ttaactatgc	4620
ggcatcagag	ca	tg				4643

<210> 5
<211> 4454
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGX104

<400> 5

gagtgcacca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcac 60
ggcggaaattt gtaaacgttaa tattttgtta aaattcgcgt taaatatttgc ttaaatcagc 120
tcattttta accaataggc cggaaatcgcc aaaatccctt ataaatcaaa agaatacgacc 180
gagatagggt tgagtgttgc tccaggttgg aacaagagtc cactattaaa gaacgtggac 240
tccaaacgtca aaggggcggaa aaccgtctat cagggcgtat gcccactacg tgaaccatca 300
cccaaataa gtttttgcg gtcgagggtgc cgtaaagctc taaatcgaa ccctaaagg 360
agcccccgat tttagagcttgc acggggaaag cggcgcgaaacg tggcgagaaa ggaagggaag 420
aaagcgaaag gacggggcgc tagggcgctg gcaagtgttag cggtcacgtc ggcgttaacc 480
accacaccccg cccgcgtttaa tgcgcgcgtc cagggcgcgt ccattcgcc ttcaggctgc 540
gcaactgttgc ggaagggcga tcgggtcgccc ccttttcgtt attaccccg ctggcgaaag 600
ggggatgtgc tgcaaggcga ttaagttggg taacgcagg gttttcccg tcacgacgtt 660
gtaaaacgac gcccagtggaa ttgttaatacg actcactata gggcgaattt aaaaaacccc 720
tcaagaccccg ttttagaggcc ccaaggggtt atgctagtga attctgcagg gtacccggg 780
atcctctaga gatccctcgat cctcgagatc cattgtgtc gaccgtggta ctcttatgg 840
gctcggaaatc tcgccaatcg tcacttctgg acttattatcg caacttctcg cccggagccaa 900
gatcatcgaa gtcggagaca caccataaggc cccgtgtctt ttcaacggag cccagaaatg 960
taagccgaaa agtgtgttgc ttcaatctt aatttttgcgaa cttttcgtatg ttcgggtatgg 1020
tcatctactgt tggacaagctt attgtctacg tcatgtccgg actctacgg gaggccatcg 1080
aaatcgagc tggaaatctgt ctccttatcg tgggtccaaact cgttattggc ggtctcatcg 1140
tcctcttcgtt cggcggatccatctt ctcggaaagg gatatggcgtt cggatccggaa atttctctt 1200
tcattggccac caacatctgtt gaaacccatgt tctggaaaggc attctcccg gcaacaatga 1260
acaccggacg tggaaacccggat ttcgaaaggc cccgtgtcttgc tctttccat cttcttgcc 1320
cccggccggat cggatcccgat gcccttcgtt cggatccggaa atttctctt 1380
tgatgaactt gatggctact ttccctcgat ttgcgggtgtt tatctacttc caaggattcc 1440
gtgtcgaccc tccaaatcaag tctggccgtt accgtggaca atacagcagc taccatca 1500
agctcttcataa caccatccaaatcaatcaatccatc tgcgttcgtc tccaaacctct 1560
acgttatctc tcaggtttgt tgcgttcgtc tagtacgggtt agatgtttat ctttctct 1620
agggtcaagt tggccgagaa attttttgcgat ttcattctca agtctgtatgg aaaaatgtt 1680
tttttcgtat gtcgcccggaa aagttccggag gaaacttctt catcaacccatc tccgggtac 1740
ggtccgataa caccggatccatc agaagctacc caactggagg actctgttac tatctttcac 1800
caccagatc tcttggacac atcttcgttgc accaaatccatc ctgcaccacg acaatggatc 1860
tcgagggtatc ttccatctactt accagttctg cggcgttcgtt tcgcggccgc gactctct 1920
acgctgttgcgat ttacttagcat aacccttgcgat ggcctctaaat cgggtcttgc ggggtttttt 1980
gagcttctcg ccctatagttt agtctgttgc tccatgttgcgat attctatagttt gtcacccat 2040
tagcttggcg taatcatgtt catagctgtt tccatgttgcgat aatttttgcgat cgttcacat 2100
tccacacaac atacgagccg gaagcataaa gtgtaaaggcc tgggttgcctt aatggatgt 2160
ctaactcaca ttaattgtgttgcgtt tgcgttcactt cccggccgtt cggatccggaa accctgttgcgtt 2220
ccagctgtatc taaatgttgcgat gccaacccgcg gggggagggc ggtttgcgtt ttggggcgtc 2280
ttccgcttcc tccgttcactt accctgttgcgat tccgttgcgtt cggatccggat gggatccgtt 2340
agctctactca aaggccgttgcgat tccgttgcgtt cccggccgtt cggatccggat gggatccgtt 2400
catgttgcgtt aaggccgttgcgat aaaaaggccgttgcgat gggatccgtt cggatccggat gggatccgtt 2460
tttcgtatagg ctccggccccc ctgcgttgcgtt tccatgttgcgtt cccggccgtt cggatccggat gggatccgtt 2520
gcccggccgttgcgtt cccggccgttgcgtt tccatgttgcgtt cccggccgtt cggatccggat gggatccgtt 2580
ctctctgttcc tccgttcactt accctgttgcgat tccgttgcgtt cggatccggat gggatccgtt 2640
cgatccgttgcgtt tccatgttgcgtt cccggccgtt cggatccggat gggatccgtt 2700
caagctggccgttgcgtt cccggccgtt cccggccgtt cccggccgtt cggatccggat gggatccgtt 2760
ctatctgttgcgtt cccggccgtt cccggccgtt cccggccgtt cggatccggat gggatccgtt 2820
taacaggattt accctgttgcgtt cccggccgtt cccggccgtt cggatccggat gggatccgtt 2880
taactacccgttcc tccgttcactt accctgttgcgtt cccggccgtt cggatccggat gggatccgtt 2940
cttcggaaatccgttcc tccgttcactt accctgttgcgtt cccggccgtt cggatccggat gggatccgtt 3000
ttttttgttcc tccgttcactt accctgttgcgtt cccggccgtt cggatccggat gggatccgtt 3060
gatctttcttcc tccgttcactt accctgttgcgtt cccggccgtt cggatccggat gggatccgtt 3120

8

catgagattta	tcaaaaaagga	tcttcaccta	gatcctttta	aattaaaaat	gaaggtttaa	3180
atcaatctaa	agtatatatg	agtaaaactt	gtctgacagt	taccaatgt	taatcagtga	3240
ggcacctatc	tcagcgatct	gtctatttcg	ttcatccata	gttcctgac	tccccgtcg	3300
gtagataact	acgatacggg	agggcttacc	atctggcccc	agtgtcga	tgataccgcg	3360
agacccacgc	tcacccggctc	cagatttac	agcaataaaac	cagccagccg	gaaggccga	3420
gcgcagaagt	ggtcctgcaa	ctttatccgc	ctccatccag	tctattaatt	gttgcggga	3480
agctagagta	agtagttcgc	cagttaatag	tttgcgcaac	gttgttggca	ttgtacagg	3540
catcggtgt	tcacgctcgt	cgttggtat	ggcttcattc	agctccggtt	cccaacgatc	3600
aaggcgagtt	acatgatccc	ccatgttgt	caaaaaagcg	gttagctct	tcgggtcctcc	3660
gatcggtgtc	agaagtaagt	tggccgcagt	gttatcactc	atggttatgg	cagcaactgca	3720
taattctctt	actgtcatgc	catccgttaag	atgcctttct	gtgactgggt	agtaactcaac	3780
caagtcattc	tgagaatacc	gcccggcg	accgagttgc	tcttgcggcg	cgtcaatac	3840
ggataatagt	gtatgacata	gcagaactt	aaaatgtc	atcattggaa	aacgttcttc	3900
ggggcgaaaa	ctctcaagga	tcttaccgc	gtttagatcc	agttcgatgt	aaccactcg	3960
tgcaccccaa	tgatcttcag	catcttttac	tttcaccagc	gtttctgggt	gagaaaaaac	4020
aggaaggcaa	aatgcccac	aaaagggaa	aaggcgaca	cggaaatgtt	gaatactcat	4080
actttctt	tttcaatatt	attgaagcat	ttatcagggt	tattgtctca	tgagcggata	4140
catatttcaa	tgttattttaga	aaaataaaca	aataggggtt	ccgcgcacat	ttcccccggaa	4200
agtgcacact	gacgtctaa	aaaccattat	tatcatgaca	ttaacctata	aaaataggcg	4260
tatcacgagg	ccctttcgtc	tcgcgcgtt	cgggtatgac	ggtaaaaacc	tctgacacat	4320
gcagctcccg	gagacggtca	cagcttgc	gtaagcggat	gccgggagca	gacaagcccc	4380
tcagggcgcg	tcagcggtg	ttggcggtg	tcggggctgg	cttaactatg	cggcatcaga	4440
gcagattgt	ctga					4454

<210> 6

<211> 4701

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGZ18

<400> 6

accacaggttt	cttgacaaa	gtggtgatct	ttccacgcaca	atggatctcg	agggatcttc	60
catacctacc	agttctgcgc	ctgcaggctcg	cggccgcgcac	tctctagacg	cgtaagctta	120
ctagcataac	cccttggggc	ctctaaacgg	gtcttgaggg	gtttttttag	cttctcgccc	180
tatagtgagt	cgttattacag	cttgagttatt	ctatagtgtc	acctaataatag	cttgcgtaa	240
tcatggtcat	agctgtttcc	tgtgtgaat	tgatatccgc	tcacaattcc	acacaacata	300
cgagccggaa	gcataaaagtgy	taaagccctgg	ggtgcctaatt	gagttagct	actcacattt	360
attgcgttgc	gctcaactgc	cgctttccag	tcggaaacc	tgtcggtcc	gtgcattaa	420
tgaatcgcc	aacgcgcggg	gagaggccgt	ttgcgttattg	ggcgccttc	cgcttcctcg	480
ctcaactgact	cgcttgcgc	ggtcgttccgg	ctggccgcag	cggtatcagc	tcactcaaag	540
gcggtaataac	ggttatccac	agaatcaggg	gataacgcag	aaaaaaacat	gtgagcaaaa	600
ggccagcaaa	aggccaggaa	ccgtaaaaaaag	gccgcgttgc	tggcgtttt	cgataggctc	660
ccccccctg	acgagcatca	caaaaatcga	cgctcaatgc	agaggtggcg	aaaccgcaca	720
ggactataaa	gataccaggc	gtttccccc	ggaagctccc	tcgtgcgtc	tcctgttccg	780
accctgcgc	ttaccggata	ctgtccccc	tttccccc	cggaagcgt	ggcgtttct	840
catagctcac	gctgttaggt	tctcagttcg	gtgttaggtcg	ttcgctccaa	gctgggctgt	900
gtgcacgaaac	cccccggtca	gccccgaccgc	tgcgccttat	ccggtaacta	tcgtcttgag	960
tccaaccgg	taagacacga	tttatcgcca	ctggcagcag	ccactggtaa	caggattagc	1020
agagcgaggt	atgtaggcgg	tgctacagag	ttcttgaagt	ggtggcctaa	ctacggctac	1080
actagaagga	cagttttgg	tatctgcgt	ctgctgaagc	cagttacatt	cggaaaaaga	1140
gttggtagct	cttgatccgg	caaacaacc	accgctggta	gccccgggtt	ttttgttgc	1200
aagcagcaga	ttacgcgcag	aaaaaaaaagg	tctcaagaag	atccctttagt	ctttctacg	1260
gggtctgacg	ctcagtgaa	cgaaaaactca	cgttaaggga	ttttggtcat	gagattatca	1320
aaaaggatct	tcacccatagat	ccttttaat	taaaaatgaa	gttttaatc	aatctaaagt	1380
atatatgagt	aaacttggtc	tgacagttac	caatgtttaa	tcagtggagc	acctatctca	1440
gcgatctgtc	tatttcgttc	atccatagtt	gcctgactcc	ccgtcgtgt	gataactacg	1500

atacgggagg gcttaccatc tggcccaagt gctgcaatga taccgcgaga cccacgctca 1560
 ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg cagaagtgg 1620
 cctgcaactt tatccgcctc catccagtct attaattgtt gccgggaagc tagagtaagt 1680
 agttcgccag ttaatagtt gcgcaacgtt gttggcattt ctacaggcat cgtggtgtca 1740
 cgctcgctgt ttggtatggc ttcatcagc tccgggttccc aacgatcaag gcgagttaca 1800
 tgatccccca ttgtgtgcaa aaaagcggtt agtccttcg gtcctccgat cttgttcaga 1860
 agtaagtgg ccgcagtgtt atcaactcatg ttatggcag cactgcataa ttctcttact 1920
 gtcatgccat ccgtaagat ctttctgtg actggtagt actcaaccaa gtcattctga 1980
 gaataccgcg cccggcgacc gatgttct tgcggcgt caatacggga taatagtgt 2040
 tgacatagca gaactttaaa agtgctcatc attggaaaac gttttcggg gcgaaaaactc 2100
 tcaaggatct taccgtgtt gagatccagt tcgatgtaa ccactcgtgc acccaactga 2160
 tcttcagcat ctttacttt caccagcggt tctgggttag caaaaacagg aaggcaaaat 2220
 gcccggaaaa agggaaataag ggcgacacgg aatgttga tactcatact ctccctttt 2280
 caatattattt gaagcatta tcagggttat tgcgtcatga gcgatatacat atttgaatgt 2340
 atttagaaaa ataaacaaaat aggggttccg cgacatattc cccgaaaaagt gccacctgac 2400
 gtctaagaaaa ccattattat catgacattt acctataaaa ataggcgat cacgaggccc 2460
 tttcgctcg cgcgtttcgg tgatgacggt gaaaacctct gacatcatca gtcggggag 2520
 acggtcacag cttgtctgtt agcggatgcc gggagcagac aagccgtca gggcggtca 2580
 gcggtgttg gcggtgtcg gggctggctt aactatgcgg catcagagca gattgtactg 2640
 agagtgccacc atatgcgtt taaaataccg cacagatgcg taaggagaaa ataccgcac 2700
 aggcaaaattt gtaaaacgtt atattttgtt aaaattcgcg ttaaatattt gtaaaatcag 2760
 ctcattttt aaccaatagg ccgaatcgg caaaatccct taaaatcaa aagaatagac 2820
 cgagataggg ttgagtgtt ttcaggtttt gaaaaagagt ccactattaa aaaaacgtgga 2880
 ctcaacgtc aaaggcgaa aaaccgtcta tcagggtcgat gcccactac gtgaaccatc 2940
 acccaatca agtttttgc ggtcgggtg cctgtttttt ctaaatcgg accctaaagg 3000
 gagccccga tttagagctt gacggggaaa gcccggcaac gtggcgagaa aggaagggaa 3060
 gaaagcgaaa ggagcggggcg cttagggcgct ggcaatgtt gggcacgc tgccgttaac 3120
 caccacaccc gccgcgttta atgcggcgct acagggcgcc tccattcgcg attcaggctg 3180
 cgcaactgtt gggagggcg atcgggtcg ggcctttcg tattacgcca gtcggcgaaa 3240
 gggggatgtg ctgcaaggcg attaagttgg gtaacgcgg gttttccca gtcacgacgt 3300
 tgtaaaacga cggccagtgta attgtatatac gactcactat agggcgaatt caaaaaacc 3360
 ctcaagaccc gtttagaggg cccaaagggt tatgttagtg aattctgcag ggtacccggg 3420
 gatctcttag agatccctcg acctcgatccat ccattgtgtt gggaaagccct tgcaaggctg 3480
 gcaagccacg tttgggtgtt ggcaccatcc tccaaaatca acaagttgt acaaaaaaagc 3540
 aggctatgcc aagtatcatgt cgattgcgtt cgcgttgcgtt atgttggctg ttttagtcgc 3600
 taccagcgtt caaattgtt tcgagatgtc gtttttacat tatcccttca tcctgattac 3660
 gacaattttc agctgttctc gctctacat ctctcttcat tgcacaatgt gtcggaatct 3720
 tcttccttgc tgcgtgtt catccaaaatg aattcacgaa tattatccat ggtgtcgat 3780
 tcttcctcat gattccatct acatatgtgt tcctcaactt atattcgctc atcaatctca 3840
 acgttatcac gtggggact cgtgaagctg tcgctaaaggc aacgggacaa aagacgaaaa 3900
 aagcgcttat ggaacaattt atagacagag tgattgtat tttttttttt gttttttttt ggattcgat 3960
 taatcgttg tcggggagaag aaggaacatg aagagagac agagaaaaatg gaaaagaaaa 4020
 tgcagagaat gtagctaggc ttgagaagta ttgaggttat ctttaattt agaaatgtga 4080
 aattaataat ttattttcgt agtggccg acgtgaagaaa aattctcgat gcaacagagg 4140
 agaaggagaa acgtgaagaaa gaaactcaaa ctgcagattt tccgattgaa gagaacgtag 4200
 agaagactca aaaagagatt cagaaggcaa accgttatgt gtggatgaca agtcatagct 4260
 tgaagtttgc tgaacgagaa aaactgaaaaa gtgcggaaaaa gttttctgg aacgagctca 4320
 tcaatgcata tctgaaaccc atcaagacga cggccagctga aatgaaaagcc gtcgcccgaag 4380
 gattggcttc tctacgaaat cagattgtt tcactattct ttcgtttaat tctttttttt 4440
 ctcttgccat cttttgcattt cagaaacaca aaaatgtgtt cagcatcaag ttctcgccaa 4500
 tcagaatgcata atattaccc ttatggtaat tcaaaaaattt ttttttttt ttctagaaaa 4560
 cttccgatgg acgaaaaatga atgagatgac tggacaatac gggaaaccg atgaaccatt 4620
 aaaaatagat ccacttggaa tggaaattgt ttgtttccctt ctaattattc tttttgttca 4680
 aactctcgga atgcttctcc a 4701

<210> 7

<211> 25

<212> DNA

10

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide primer C04H5.6F

<400> 7

tgctcagaga gtttctcaac gaacc

25

<210> 8

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer C04H5.6R

<400> 8

caatgttagt tgctaggacc acctg

25

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer K11D9.2bF

<400> 9

cagccgatct ccgtcttggt

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer K11D9.2bR

<400> 10

ccgagggcaa gacaacgaag

20

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide
primer Y57G11C.15F

<400> 11

accgtggtagt tcttatggag ctcg

24

<210> 12

11

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer Y57G11C.15R

<400> 12
tgcagtggat tgggtcttcg

20

<210> 13
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer T25G3.2F

<400> 13
ggggacaagt ttgtacaaaa aagcaggcta tgccaaagtac atgtcgattg cg

52

<210> 14
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer T25G3.2R

<400> 14
ggggaccact ttgtacaaga aagctgggtt ggagaaggcat tccgagagtt tg

52

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/10 C12N9/22 C07K14/435 C12N15/66 C12N15/70
C12N1/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TIMMONS L ET AL: "Specific interference by ingested dsRNA" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 395, no. 6705, 29 October 1998 (1998-10-29), page 854 XP002103601 ISSN: 0028-0836 the whole document</p> <p>---</p> <p>FIRE A ET AL: "Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i>" NATURE, GB, MACMILLAN JOURNALS LTD. LONDON, vol. 391, 19 February 1998 (1998-02-19), pages 806-811, XP002095876 ISSN: 0028-0836 cited in the application the whole document</p> <p>---</p> <p>---</p>	1-4, 12-21, 23-25, 28-31, 34-39
A		1-4

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 July 2001

Date of mailing of the international search report

20/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SHARP PHILLIP A: "RNAi and double-strand RNA." GENES & DEVELOPMENT, vol. 13, no. 2, 15 January 1999 (1999-01-15), pages 139-141, XP002171268 ISSN: 0890-9369 the whole document ---	1-4
A	RAY C ET AL: "GUT-SPECIFIC AND DEVELOPMENTAL EXPRESSION OF A CAENORHABDITIS ELEGANS CYSTEINE PROTEASE GENE" MOLECULAR AND BIOCHEMICAL PARASITOLOGY, NL, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 51, 1992, pages 239-249, XP000572340 ISSN: 0166-6851 abstract ---	2-4, 8
A	RAND J B ET AL: "GENETIC PHARMACOLOGY: INTERACTIONS BETWEEN DRUGS AND GENE PRODUCTS IN CAENORHABDITIS ELEGANS" METHODS IN CELL BIOLOGY, LONDON, GB, vol. 84, 1995, pages 187-204, XP000956211 page 190, paragraph 1 -page 194, paragraph 4 ---	1-4, 8
A	AVERY LEON ET AL: "The Caenorhabditis elegans unc-31 gene affects multiple nervous system-controlled functions." GENETICS, vol. 134, no. 2, 1993, pages 455-464, XP001011453 ISSN: 0016-6731 the whole document ---	2-4, 8
A	TAGESSON C ET AL: "INFLUENCE OF SURFACE-ACTIVE FOOD ADDITIVES ON THE INTEGRITY AND PERMEABILITY OF RAT INTESTINAL MUCOSA" FOOD AND CHEMICAL TOXICOLOGY, vol. 22, no. 11, 1984, pages 861-864, XP001009621 ISSN: 0278-6915 the whole document ---	8
		-/-

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	LYON CHRISTOPHER J ET AL: "The <i>C. elegans</i> apoptotic nuclease NUC-1 is related in sequence and activity to mammalian DNase II." GENE (AMSTERDAM), vol. 252, no. 1-2, 11 July 2000 (2000-07-11), pages 147-154, XP001009494 ISSN: 0378-1119 abstract; figure 3 page 151, right-hand column, paragraph 2 -page 153, right-hand column, paragraph 2 ---	6,7
P,X	WO 00 01846 A (MORTIER KATHERINE ;DEVGEN NV (BE); BOGAERT THIERRY (BE); PLAETINCK) 13 January 2000 (2000-01-13) cited in the application page 8, line 9 -page 10, line 22 page 12, line 14 -page 23, line 2 figures 5,9; examples 1-4 ---	1-4, 12-21, 23-25, 28-31, 34-39
P,X	WO 00 63425 A (FEICHTINGER RICHARD ;BEGHYN MYRIAM (BE); DEVGEN NV (BE); BOGAERT T) 26 October 2000 (2000-10-26) abstract page 2, line 14-30 page 6, line 18-33 page 7, line 12 -page 9, line 28 page 12, line 20 -page 13, line 25; example 3 ---	2-5,8,9, 29-33
T	TIMMONS LISA ET AL: "Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in <i>Caenorhabditis elegans</i> ." GENE (AMSTERDAM), vol. 263, no. 1-2, 2001, pages 103-112, XP001009512 ISSN: 0378-1119 the whole document -----	1-4, 12-21, 23-26, 28-31, 34-39

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/13149

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0001846	A 13-01-2000	AU 4907999 A		24-01-2000
		EP 1093526 A		25-04-2001
		GB 2349885 A		15-11-2000
		NO 20010019 A		05-03-2001
WO 0063425	A 26-10-2000	AU 3984600 A		02-11-2000
		GB 2351152 A		20-12-2000

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.